A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults.

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD). It is typically characterized by degeneration of nigrostriatal dopaminergic neurons and misfolded α-synuclein (Lewy bodies) in surviving neurons. In addition to the classic motor signs, non-motor manifestations in PD affect most patients. In this regard, cognitive decline and neuropsychiatric manifestations such as apathy are common. According to the International Society for Central Nervous System Clinical Trials Methodology (ISCTM), apathy is defined as a quantitative reduction in goal-directed activity compared to the patient's previous level of functioning, affecting at least two of the three dimensions of apathy (behavior/cognition, emotion, and social interaction). It has a reported prevalence of 40% among PD patients and is often associated with greater disease severity and lower cognitive scores, more frequently in executive functions, as well as lower quality of life. Furthermore, apathy occurs more frequently in PD patients with dementia (PDD) (54%) and seems to be a risk factor for conversion to dementia in this population. Additionally, the presence of dementia has been identified as a risk factor for subsequent development of apathy.